PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chiara Tarantelli, Lisa Argnani, Pier Luigi Zinzani, Francesco Bertoni
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	lymphoma PI3K inhibitors T-cells B-cells macrophages chemokine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a69096643d264eb8a6a9cd140510591d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a69096643d264eb8a6a9cd140510591d
record_format	dspace
spelling	oai:doaj.org-article:a69096643d264eb8a6a9cd140510591d2021-11-11T15:33:59ZPI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients10.3390/cancers132155352072-6694https://doaj.org/article/a69096643d264eb8a6a9cd140510591d2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5535https://doaj.org/toc/2072-6694The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδ inhibitors exert on the immune system with a particular focus on the T-cell compartment.Chiara TarantelliLisa ArgnaniPier Luigi ZinzaniFrancesco BertoniMDPI AGarticlelymphomaPI3K inhibitorsT-cellsB-cellsmacrophageschemokineNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5535, p 5535 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lymphoma PI3K inhibitors T-cells B-cells macrophages chemokine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	lymphoma PI3K inhibitors T-cells B-cells macrophages chemokine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Chiara Tarantelli Lisa Argnani Pier Luigi Zinzani Francesco Bertoni PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
description	The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδ inhibitors exert on the immune system with a particular focus on the T-cell compartment.
format	article
author	Chiara Tarantelli Lisa Argnani Pier Luigi Zinzani Francesco Bertoni
author_facet	Chiara Tarantelli Lisa Argnani Pier Luigi Zinzani Francesco Bertoni
author_sort	Chiara Tarantelli
title	PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
title_short	PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
title_full	PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
title_fullStr	PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
title_full_unstemmed	PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
title_sort	pi3kδ inhibitors as immunomodulatory agents for the treatment of lymphoma patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a69096643d264eb8a6a9cd140510591d
work_keys_str_mv	AT chiaratarantelli pi3kdinhibitorsasimmunomodulatoryagentsforthetreatmentoflymphomapatients AT lisaargnani pi3kdinhibitorsasimmunomodulatoryagentsforthetreatmentoflymphomapatients AT pierluigizinzani pi3kdinhibitorsasimmunomodulatoryagentsforthetreatmentoflymphomapatients AT francescobertoni pi3kdinhibitorsasimmunomodulatoryagentsforthetreatmentoflymphomapatients
_version_	1718435200979959808

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

Ejemplares similares